Sly Saint
Senior Member (Voting Rights)
The industry that drives the production of systematic reviews today is financed by some of the most influential agencies in medical research. Cochrane, for example, points to three funders providing over £1 million each—the UK's National Institute for Health Research (NIHR), the US National Institutes of Health (NIH), and Australia's National Health and Medical Research Council (NHMRC).
Cochrane's claims are big: trusted evidence, informed decisions, better health. But what if the astonishing energy, commitment, and productivity of the systematic review community are poisoning rather than nourishing medical practice?
This question has been repeatedly asked by one of the UK's leading clinical trialists, Ian Roberts, Professor of Epidemiology and Public Health and Co-Director of the Clinical Trials Unit at the London School of Hygiene & Tropical Medicine. It is a question that can no longer be avoided.
Roberts argues that trust could be restored if reviewers included only prospectively registered trials and checked that trial data were real and accurate.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32766-7/fulltext